Airgain Unveils Groundbreaking Solar-Powered 5G Smart Repeater Pioneering the Future of Sustainable Connectivity
Airgain, Inc. (NASDAQ: AIRG) has achieved a major breakthrough in 5G expansion with the successful launch of a self-sustaining, solar-powered Smart Network-Controlled Repeater (NCR) branded as Lighthouse SolarTM.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250225231962/en/
Airgain has launched Lighthouse Solar, a solar-powered 5G smart repeater (Photo: Airgain)
Fully detached from the power grid, this revolutionary technology unlocks new revenue opportunities for telecom operators, accelerates 5G adoption in remote areas, and reinforces Airgain’s leadership in next-generation wireless solutions.
With telecom infrastructure expansion often hindered by geographical challenges and high deployment costs, Airgain’s Lighthouse SolarTM Smart NCR system offers a highly scalable, fast to market, and cost-efficient alternative to traditional fiber and power-dependent solutions. Recent field trial demonstrations confirm its transformative market potential:
- 20% 5G coverage expansion, increasing addressable market reach in rural and urban areas.
- Unprecedented speed transformation observed in the recent trial– soaring from 1 Mbps on existing 4G networks to an average of over 250 Mbps, with peak speeds hitting 425 Mbps, even in previously underserved locations.
- More than 50% improvement in spectrum efficiency, maximizing network utilization and boosting operator profitability.
- Superior link quality, enhancing data throughput in challenging environments.
- Rapid deployment in less than a day, eliminating reliance on power grids and fiber backhaul, reducing Capital Expenditures and Operating Expenditures for telecom carriers.
“This breakthrough positions Airgain at the forefront of the 5G infrastructure revolution,” said Dr. Ali Sadri, Chief Technology Officer at Airgain. “By offering a sustainable, grid-independent, and rapidly deployable solution, we are enabling telecom operators to expand their networks at lower costs, increase service reliability, and drive greater monetization opportunities—all while advancing global connectivity.”
With push for sustainable telecom solutions worldwide, and rising demand for 5G coverage expansion, Airgain’s Lighthouse SolarTM NCR system presents a compelling investment opportunity in the evolving digital infrastructure market. By removing traditional deployment bottlenecks, this solution opens the door to faster 5G rollouts, enhanced user experiences and significantly improves customer satisfaction and long-term cost savings for service providers.
Airgain will be showcasing its Lighthouse Solar solution at this year’s Mobile World Congress (MWC) event in Barcelona from March 3 – 6 where they will be hosting an event with partners Omantel to discuss sustainable and smart 5G wireless system solutions. Find out more and register to attend the event, here.
Notes to editors
Airgain executives will also be available for briefings at Mobile World Congress (MWC) Barcelona, from March 3 – 6 to discuss the transformative benefits of Lighthouse Solar. Please get in touch if you would be interested in booking an interview.
About Airgain, Inc.
Headquartered in San Diego, California, Airgain, Inc. (NASDAQ: AIRG) is a leading provider of advanced wireless connectivity solutions that drive cutting-edge innovation in 5G technology. We are committed to delivering high-performance, cost-effective, and energy-efficient wireless solutions that enable rapid market deployment. Our mission is to connect the world through integrated, innovative, and optimized wireless solutions. Our diverse product portfolio serves three primary markets: enterprise, automotive, and consumer.
For more information, visit airgain.com or follow us on LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250225231962/en/
Contacts
Media contact:
Martyn Gettings, Tank PR
martyn.gettings@tank.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom